

CASE STUDY

Enrolling 600+ Participants for a Fully Decentralized Asthma Trial (BATURA)

The Objective

Avillion and AstraZeneca partnered with Velocity to test a novel asthma treatment for teens and adults as part of the fully decentralized BATURA trial. Targeting people aged 12 and older with asthma, Velocity was selected to support the trial in the U.S.

- → Global enrollment goal: 2,500 participants
- → Velocity goal: 569 participants across 14 sites (U.S.)
- → Enrollment window: 12 months

The Result

As one of seven networks (56 sites) involved, Velocity delivered 24% of trial participants. Emerging as the highest enrolling network of brick-and-mortar sites, Velocity exceeded its enrollment goal and demonstrated its ability to efficiently support a decentralized trial.

Velocity delivered 604 participants (24% of trial, 106% of target) with ~43 enrolled per site.

In October 2024, after an independent data monitoring committee recommended the trial stop early due to overwhelming efficacy at pre-planned analysis, Avillion and AstraZeneca announced positive results from the BATURA trial.

Given our positive experience with Velocity, Avillion intends to establish a close working relationship and engage early on projects that could benefit from Velocity's high-quality patient enrollment capability."

Robert Rees, PhD, Sr. Dir., Clinical Programs, Avillion



The Trial

Client: Avillion and AstraZeneca

Title: A Multicenter, Randomized, Double-blind, Parallel group, Eventdriven, Decentralized, Phase III Study comparing PT027 (Budesonide/ Albuterol) with PT007 (Albuterol) Administered as needed in Adolescents and Adults with Asthma (BATURA)

Target population: Ages ≥12, with asthma, and treated with short-acting beta-agonists (SABA) alone, low-dose inhaled corticosteroids (ICS) plus SABA, or leukotriene modifiers plus SABA



Top Velocity Sites Involved

- Austin, TX
- Lafayette, LA
- Boise, ID
- Medford, OR
- Denver, CO
- Providence, RI
- Greenville, SC
- Valparaiso, IN